Neurologic complications after hematopoietic stem cell transplantation are frequently life-
threatening, and their clinical management can be highly challenging. A wide spectrum of …

Hematopoietic stem cell transplantation (HCT) represents a curative treatment option for
certain malignant and nonmalignant hematological diseases. Conditioning regimens before …

In cancer patients, thrombocytopenia can result from bone marrow infiltration or from
anticancer medications and represents an important limitation for the use of antithrombotic …

Haematopoietic stem cell transplantation (HSCT) is an established treatment for a variety of
malignant and nonmalignant conditions. Pulmonary complications, both infectious and …

The optimal management of hematologic malignancy‐associated venous thromboembolism
(VTE) in patients with moderate‐to‐severe thrombocytopenia is unclear. This is a …

Allogeneic hematopoietic stem cell transplantation (HSCT) is an established treatment with
curative intent for hematologic malignancies and several nonmalignant conditions …

Aims To estimate the incidence and predictors of symptomatic arterial and venous
thromboembolic events (TEE) from intravenous immunoglobulin (IVIg) therapy according to …

Hematologic malignancies are the main clinical indications for allogeneic hematopoietic
stem cell transplantation (HSCT). In previous years, the evolution of this procedure …

Cancer patients have varying incidence, depth and duration of thrombocytopenia. The
mainstay of managing severe chemotherapy-induced thrombocytopenia (CIT) in cancer is …

Hematopoietic cell transplant (HCT) recipients are at risk for thromboembolic and bleeding
complications. There is limited evidence regarding the optimal approach to managing …